Alto Neuroscience (NYSE:ANRO) Stock Price Down 7.2% – What’s Next?

Alto Neuroscience, Inc. (NYSE:ANRO)’s share price was down 7.2% on Thursday . The stock traded as low as $19.59 and last traded at $19.89. Approximately 36,007 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 200,886 shares. The stock had previously closed at $21.43.

Analyst Ratings Changes

A number of research analysts recently issued reports on ANRO shares. Weiss Ratings restated a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Alto Neuroscience from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Jefferies Financial Group lifted their target price on shares of Alto Neuroscience from $15.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. BTIG Research increased their price target on shares of Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Finally, Robert W. Baird raised their price objective on shares of Alto Neuroscience from $16.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $26.50.

Alto Neuroscience Stock Down 6.8%

The company has a quick ratio of 15.42, a current ratio of 15.42 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $620.70 million, a PE ratio of -8.72 and a beta of 2.52. The firm’s fifty day moving average is $17.31 and its 200-day moving average is $12.13.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC boosted its position in shares of Alto Neuroscience by 13.7% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock worth $69,000 after purchasing an additional 2,055 shares in the last quarter. Peapod Lane Capital LLC boosted its holdings in Alto Neuroscience by 1.1% during the third quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock worth $1,136,000 after buying an additional 3,106 shares in the last quarter. Torren Management LLC acquired a new position in Alto Neuroscience during the fourth quarter worth about $62,000. XTX Topco Ltd increased its holdings in Alto Neuroscience by 32.2% in the fourth quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock valued at $371,000 after buying an additional 5,078 shares in the last quarter. Finally, Citizens Financial Group Inc. RI increased its holdings in Alto Neuroscience by 19.0% in the third quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company’s stock valued at $161,000 after buying an additional 6,394 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.